Literature DB >> 1636379

Metabolically dependent blood-brain barrier breakdown in chronic relapsing experimental allergic encephalomyelitis.

C P Hawkins1, P M Munro, D N Landon, W I McDonald.   

Abstract

We have studied chronic relapsing experimental allergic encephalomyelitis (CREAE), a model of immune-mediated demyelination, using gadolinium (Gd)-enhanced magnetic resonance imaging in vivo and the blood-brain barrier (BBB) markers, lanthanum nitrate and Gd nitrate, histologically. In regions of the spinal cord showing Gd enhancement, there was evidence for vesicular transport as a mechanism of BBB breakdown in CREAE, shown by an increased number of endothelial vesicles containing lanthanide (lanthanum or Gd, whichever had been perfused) and deposition of tracer in the perivascular space; tight interendothelial junctions remained intact. Prior perfusion with 2,4-dinitrophenol, a metabolic inhibitor, suppressed the appearance of endothelial vesicles containing lanthanide and tracer in the perivascular space. We conclude that an important contribution to BBB breakdown in CREAE is mediated by a metabolic change in the endothelial cells associated with increased vesicular transport.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1636379     DOI: 10.1007/bf00299413

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  25 in total

Review 1.  Transcytosis of macromolecules through the blood-brain barrier: a cell biological perspective and critical appraisal.

Authors:  R D Broadwell
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

2.  Hypothesis: a role for tumor necrosis factor in immune-mediated demyelination and its relevance to multiple sclerosis.

Authors:  C F Brosnan; K Selmaj; C S Raine
Journal:  J Neuroimmunol       Date:  1988-04       Impact factor: 3.478

3.  Maintenance of the integrity of the blood-brain barrier in the rat during an in situ saline-based perfusion.

Authors:  J Greenwood; P J Luthert; O E Pratt; P L Lantos
Journal:  Neurosci Lett       Date:  1985-05-14       Impact factor: 3.046

Review 4.  Morphofunctional aspects of the normal and pathological blood-brain barrier.

Authors:  J Cervós-Navarro; J Artigas; B J Mrsulja
Journal:  Acta Neuropathol Suppl       Date:  1983

5.  The lesion of multiple sclerosis: imaging of acute and chronic stages.

Authors:  R A Koopmans; D K Li; J J Oger; J Mayo; D W Paty
Journal:  Neurology       Date:  1989-07       Impact factor: 9.910

6.  The effect of a metabolic inhibitor upon the properties of the cerebral vasculature during a whole-head saline perfusion of the rat.

Authors:  P J Luthert; J Greenwood; O E Pratt; P L Lantos
Journal:  Q J Exp Physiol       Date:  1987-01

7.  Blood-brain barrier in chronic relapsing experimental allergic encephalomyelitis: a correlative study between cerebrospinal fluid protein concentrations and tracer leakage in the central nervous system.

Authors:  K Kitz; H Lassmann; D Karcher; A Lowenthal
Journal:  Acta Neuropathol       Date:  1984       Impact factor: 17.088

8.  Interleukin 2-activated human lymphocytes exhibit enhanced adhesion to normal vascular endothelial cells and cause their lysis.

Authors:  N K Damle; L V Doyle; J R Bender; E C Bradley
Journal:  J Immunol       Date:  1987-03-15       Impact factor: 5.422

9.  Heterogeneity of blood-brain barrier changes in multiple sclerosis: an MRI study with gadolinium-DTPA enhancement.

Authors:  A G Kermode; P S Tofts; A J Thompson; D G MacManus; P Rudge; B E Kendall; D P Kingsley; I F Moseley; E P du Boulay; W I McDonald
Journal:  Neurology       Date:  1990-02       Impact factor: 9.910

10.  The capillaries in acute and subacute multiple sclerosis plaques: a morphometric analysis.

Authors:  W J Brown
Journal:  Neurology       Date:  1978-09       Impact factor: 9.910

View more
  1 in total

1.  Neurovascular damage in experimental allergic encephalomyelitis: a target for pharmacological control.

Authors:  C Bolton
Journal:  Mediators Inflamm       Date:  1997       Impact factor: 4.711

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.